Abstract P6-17-17: Pertuzumab, trastuzumab, and docetaxel for HER2-positive early or locally advanced breast cancer in the neoadjuvant setting: Efficacy and safety analysis of a randomized phase III study in Asian patients (PEONY)

作者
Zhimin Shao,Da Pang,Hongjian Yang,Wei Li,Shanshan Wang,S Cui,Ning Liao,Yi Wang,Chao Wang,Y-C Chang,Hao Wang,SY Kang,Z Jiang,Jackson Liang Yao Li,Juan Zhou,Betsy Althaus,Yan‐Ping Mao,Jennifer Eng‐Wong
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:79 (4_Supplement): P6-17 被引量:3
标识
DOI:10.1158/1538-7445.sabcs18-p6-17-17
摘要

Abstract Background Pertuzumab and trastuzumab (P and H; F. Hoffmann-La Roche Ltd, Basel, CH) bind to distinct HER2 subdomains and have complementary modes of anticancer activity in HER2-positive breast cancer (BC). A global Phase II study (NeoSphere) reported that neoadjuvant treatment with P+H+docetaxel (D) significantly increased breast pathologic complete response (bpCR) vs H+D in patients (pts) with early/locally advanced/inflammatory HER2-positive BC (Gianni et al. Lancet Oncol 2012). PEONY (NCT02586025), a randomized, multicenter, double-blind, placebo-controlled, Phase III trial conducted in an Asian population (mainland China, Taiwan, Korea, Thailand), primarily compared the efficacy, safety, and tolerability of P+H+D vs placebo (Pla)+H+D in the neoadjuvant setting. We present data from the primary analysis. Methods Pts with centrally confirmed HER2-positive early (T2–3, N0–1)/locally advanced (T2–3, N2 or N3; T4, any N) BC were randomized 2:1 to 4 cycles of P+H+D or Pla+H+D every 3 weeks, before surgery: P, 840 mg loading/420 mg maintenance doses (or Pla); H, 8 mg/kg loading/6 mg/kg maintenance; D, 75 mg/m2. Post-surgery, pts received 3 cycles of fluorouracil, epirubicin, and cyclophosphamide followed by 13 cycles of P+H or Pla+H for up to 1 year (total of 17 HER2-targeted therapy cycles). The primary endpoint was total pCR rate (tpCR; absence of any residual invasive cancer in the breast and lymph nodes [ypT0/is, ypN0]) assessed by independent review committee (IRC) when pts completed surgery with a tpCR assessment. Missing/invalid assessments were considered residual disease. Results A total of 329 pts were randomized: 219 to P, 110 to Pla. Baseline characteristics were well balanced. Most pts had early BC (69.6%) and were from mainland China (79.3%). In the intention-to-treat population, the tpCR rate by IRC was 39.3% in the P arm and 21.8% in the Pla arm; a clinically and statistically significant difference of 17.5% (95% CI 6.9–28.0; p=0.0014). The local pathologist-assessed tpCR rates were 39.3% and 20.9%, respectively. A consistent treatment benefit of P vs Pla was observed in subgroups. Incidences of grade ≥3 adverse events (Aes) were 48.6% in the P arm and 41.8% in the Pla arm. Of the most common grade 3 Aes (≥3% of pts), neutropenia was higher in the P arm (38.1% vs 32.7%). Of the most common any-grade Aes (≥5%), diarrhea was higher in the P arm (38.5% vs 16.4%). No heart failure (New York Heart Association Functional Classification III or IV) or significant left ventricular ejection fraction decline events (≥10 percentage points from baseline and to <50%) were observed during neoadjuvant therapy. Conclusions PEONY met its primary endpoint: P+H+D resulted in a clinically meaningful and statistically significant improvement in the tpCR rate by IRC vs Pla+H+D for the neoadjuvant treatment of HER2-positive early/locally advanced BC in Asian pts. Safety data were in line with the known P safety profile and generally comparable between treatment arms. Results were similar to NeoSphere, and confirm that P+H+D provides superior anticancer activity to H+D alone. Citation Format: Shao Z, Pang D, Yang H, Li W, Wang S, Cui S, Liao N, Wang Y, Wang C, Chang Y-C, Wang H, Kang SY, Jiang Z, Li J, Zhou J, Althaus B, Mao Y, Eng-Wong J. Pertuzumab, trastuzumab, and docetaxel for HER2-positive early or locally advanced breast cancer in the neoadjuvant setting: Efficacy and safety analysis of a randomized phase III study in Asian patients (PEONY) [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-17-17.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
Evander完成签到,获得积分10
1秒前
小马甲的应助被科研通管家采纳,获得10
1秒前
YW完成签到,获得积分10
2秒前
2秒前
科研通AI2S的应助被科研通管家采纳,获得10
2秒前
2秒前
伊啊亚完成签到,获得积分10
2秒前
Hello的应助被科研通管家采纳,获得10
2秒前
斯文若血发布了新的文献求助10
2秒前
null的应助被AURORA采纳,获得10
3秒前
FashionBoy的应助被科研通管家采纳,获得10
4秒前
田様的应助被不舍天真采纳,获得10
4秒前
香蕉觅云的应助被科研通管家采纳,获得10
4秒前
4秒前
华仔的应助被科研通管家采纳,获得10
4秒前
molihuakai的应助被科研通管家采纳,获得10
4秒前
4秒前
wanci的应助被科研通管家采纳,获得30
4秒前
无极微光的应助被科研通管家采纳,获得20
4秒前
Ava的应助被科研通管家采纳,获得10
5秒前
5秒前
Orange的应助被科研通管家采纳,获得10
5秒前
5秒前
烟花的应助被科研通管家采纳,获得10
5秒前
5秒前
我是老大的应助被科研通管家采纳,获得10
5秒前
科研小牛完成签到,获得积分10
5秒前
evildoer发布了新的文献求助10
5秒前
儒雅的蓝天完成签到,获得积分10
6秒前
7秒前
8秒前
8秒前
爆米花的应助被xm采纳,获得10
9秒前
秋彤完成签到,获得积分20
9秒前
zaka发布了新的文献求助10
9秒前
纯真忆安发布了新的文献求助10
10秒前
田様的应助被steins采纳,获得10
10秒前
11秒前
AAA发布了新的文献求助10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8163922
求助须知:如何正确求助?哪些是违规求助? 9557995
关于积分的说明 21743022
捐赠科研通 7754548
什么是DOI,文献DOI怎么找? 3428401
关于科研通互助平台的介绍 2553053
邀请新用户注册赠送积分活动 2473008